The DOI matches its Crossref record.
Serum Tartrate-resistant Acid Phosphatase 5b Is a Specific and Sensitive Marker of Bone Resorption
Abstract
Bone-resorbing osteoclasts and activated macrophages express high amounts of type 5 tartrate-resistant acid phosphatase (TRACP; EC 3.1.3.2) (1). Osteoclasts secrete TRACP into the circulation, and serum TRACP has been considered a potentially useful marker of bone resorption. Several technical problems have prevented the use of serum TRACP as a specific marker of bone resorption. Early enzymatic assays lacked specificity because of the presence of interfering acid phosphatases derived from platelets and erythrocytes (2)(3). Serum TRACP can be determined by use of fluoride (4) or by immunoassays with antibodies specific for TRACP (5)(6)(7)(8)(9). However, there are two forms of TRACP in the serum, namely TRACP 5a and TRACP 5b. Of these, TRACP 5b is derived from osteoclasts, whereas TRACP 5a originates from other, as yet unidentified sources (10)(11)(12). Two diagnostic assays have been developed recently for serum TRACP 5b: a kinetic assay based on the use of specific inhibitors (13), and an immunoassay based on a highly characterized specific monoclonal antibody (12). The TRACP 5b-specific immunoassay has been shown to be a useful method for monitoring antiresorptive therapy (12). We have now further characterized the immunoassay by studying the clinical specificity and clinical sensitivity of serum TRACP 5b in various bone diseases and nonskeletal diseases. We obtained serum samples from 303 individuals after written informed consent. At the time of sampling, none of the subjects was receiving antiosteoporotic treatment. Healthy premenopausal women, healthy postmenopausal women, and breast cancer (BC) patients without evidence of bone metastases (BC−) were included as control populations. Patients with bone diseases included subjects with primary vertebral osteoporosis (OPO), osteopenia, active Paget disease of bone, and BC patients with overt bone metastases (BC+). All patients with OPO had at least one vertebral compression fracture. Patients with chronic hepatic dysfunction (HF; n = 17), chronic renal failure (RF; n = 49), and rheumatoid arthritis (RA; n = 40) were included as reference populations. All patients with RF had endstage renal disease, and they had been on chronic hemodialysis for several years (mean duration, 5 years) at the time of sample collection. The study was approved by the local ethics committees and performed in accordance with the Declaration of Helsinki. Serum TRACP 5b activity was measured with a solid-phase immunofixed enzyme activity assay as described (12), using TRACP 5b purified from human osteoclasts as a calibrator (7). The distribution of TRACP 5b activity was within reference values in the control groups, and statistical analysis was performed using one-way ANOVA. The interassay CV was 2.2%, and the intraassay CV was 1.8%. The reference interval (mean ± 2 SD of healthy premenopausal women) of TRACP 5b activity in serum was 0.50–3.80 U/L. Compared with healthy premenopausal women, serum TRACP 5b activity was significantly higher (P <0.001) in healthy postmenopausal women and in all groups of patients with bone diseases (Table 1 and Fig. 1A ). The clinical specificity of TRACP 5b (percentage of healthy premenopausal women with TRACP 5b activity within reference values) was 95.0%, and the clinical sensitivity (percentage of individuals in a disease group with TRACP 5b activity above reference values) was 48.3% in osteopenia, 81.3% in OPO, 71.4% in Paget disease, and 80.0% in BC+ subjects (Fig. 1A ). Serum TRACP 5b activity in healthy women and in patients with metabolic bone diseases (mean ± SD). Serum TRACP 5b activity in healthy women and in patients with metabolic bone diseases (mean ± SD). Serum TRACP 5b in bone diseases and nonskeletal diseases. (A), serum TRACP 5b activity in healthy women and patients with metabolic bone diseases. Pre, premenopausal; Post, postmenopausal; OPE, osteopenia; PD, Paget disease. (B), serum TRACP 5b, bone sialoprotein (BSP), CTX, and NTX in BC patients. (C), serum TRACP 5b activity (5b), total TRACP mass (Total), and NTX in patients with nonskeletal diseases. The results in B and C are given as relative amounts, where the upper limit of normal for each marker is 1. The upper limit of normal is the mean + 2 SD of premenopausal women in A and C and the mean + 2 SD of BC− in B. The lines show the upper limits of normal. The clinical sensitivity in BC+ was substantially higher for TRACP 5b than for other serum markers of bone resorption (Fig. 1B ), including cross-linked N- and C-terminal telopeptides of type I collagen (NTX and CTX, respectively) and bone sialoprotein. Concentrations of all markers in the BC− group were within the reference interval. Reference values for all markers in this study were obtained from measurements of healthy premenopausal women and were comparable to published reference values. Two enzymatic pathways are involved in osteoclastic bone resorption, one involving cathepsin K and releasing NTX and CTX from bone coll
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Epidemiology, etiology, and diagnosis of osteoporosis
Lane, N. E. (2006) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2005.08.047 · Cited by 1,293
Bone turnover markers: Emerging tool in the management of osteoporosis
Shetty, S., Kapoor, N., Bondu, J. D., Thomas, N., & Paul, T. V. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.192914 · Cited by 330
“[24] Due to the fact that cathepsin K is expressed and secreted by osteoclasts during active bone resorption, cathepsin K, and specifically its circulating form, it may be a useful and specific biochemical marker of osteoclastic activity.”
BackgroundTorvinen, S., Kannus, P., Sievänen, H., Järvinen, T. A., Pasanen, M., Kontulainen, S., Nenonen, A., Järvinen, T. L., Paakkala, T., Järvinen, M., et al. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.5.876 · Cited by 322
Biochemical Markers of Bone Metabolism and Prediction of Fracture in Elderly Women
Gerdhem, P., Ivaska, K. K., Alatalo, S. L., Halleen, J. M., Hellman, J., Isaksson, A., Pettersson, K., Väänänen, H. K., Åkesson, K., & Obrant, K. J. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301244 · Cited by 283
Self-citationMiyazaki, T., Matsunaga, T., Miyazaki, S., Hokari, S., & Komoda, T. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20201 · Cited by 41
Metadata
- Authors
- Halleen, J. M., Alatalo, S. L., Janckila, A. J., Woitge, H. W., Seibel, M. J., & Väänänen, H. K.
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-03-01
- Volume
- 47
- Issue
- 3
- Pages
- 597-600
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W1911507091
- Cited by
- 158
- References
- 0
- FWCI
- 2.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serum Tartrate-resistant Acid Phosphatase 5b Is a Specific and Sensitive Marker of Bone Resorption. https://app.cochat.ai/papers/10.1093/clinchem/47.3.597
- The paper
- Halleen, J. M., Alatalo, S. L., Janckila, A. J., Woitge, H. W., Seibel, M. J., & Väänänen, H. K. (2001). Serum Tartrate-resistant Acid Phosphatase 5b Is a Specific and Sensitive Marker of Bone Resorption. Clinical Chemistry. https://doi.org/10.1093/clinchem/47.3.597
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.